Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1990-1996

  Pantel, Alix ^a   Petrella, Stéphanie ^a,c   Veziris, Nicolas ^a,b,c   Brossier, Florence ^a,b,c   Bastian, Sylvaine ^c   Jarlier, Vincent ^a,b,c   Mayer, Claudine ^d,e,f   Aubry, Alexandra ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Ctr Natl de Reference des Mycobacteries et de la Resistance des Mycobacteries Aux Antituberculeux   (France)

^d INSTITUT PASTEUR   (France)

^e CNRS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME INHIBITION; ESCHERICHIA COLI; GENE OVEREXPRESSION; MINIMUM INHIBITORY CONCENTRATION; MUTAGENESIS; MUTANT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA, BACTERIAL; DNA, SUPERHELICAL; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTAGENESIS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PLASMIDS; TUBERCULOSIS;

EID: 84858690634     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06272-11     Document Type: Article

References (33)

1. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E. 2004. Mycobacterium tuberculosisDNAgyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother. 48:1281-1288. (Pubitemid 38405482)
2. Aubry A, et al. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104-112. (Pubitemid 43042909)
3. Blumberg HM, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
4. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. 2010. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 48:1683-1689.
5. Canetti G, Rist N, Grosset J. 1963. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation. Rev. Tuberc. Pneumol. (Paris) 27:217-272.
6. Cui Z, Wang J, Lu J, Huang X, Hu Z. 2011. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect. Dis. 11:78.
7. Dauendorffer JN, et al. 2003. Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. J. Clin. Microbiol. 41:1311-1315.
8. Duong DA, et al. 2009. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob. Agents Chemother. 53:4835-4839.
9. Feuerriegel S, et al. 2009. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob. Agents Chemother. 53:3353-3356.
10. Hillemann D, Rusch-Gerdes S, Richter E. 2009. Feasibility of the Geno-Type MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 47:1767-1772.
11. Hooper DC, Rubinstein E (ed). 2003. Quinolone antimicrobial agents, 3rd ed. ASM Press, Washington, DC.
12. Huang WL, Chi TL, Wu MH, Jou R. 2011. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 49: 2502-2508.
13. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. 2009. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 4:e6914.
14. Kiet VS, et al. 2010. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 48:2934-2939.
15. Kim H, et al. 2011. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. Antimicrob. Agents Chemother. 55:3661-3667.
16. Kocagoz T, et al. 1996. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 40:1768-1774. (Pubitemid 26277791)
17. Kontsevaya I, et al. 2011. Evaluation of two molecular assays for rapid detection of Mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance settings. J. Clin. Microbiol. 49:2832-2837.
18. Matrat S, et al. 2006. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob. Agents Chemother. 50:4170-4173. (Pubitemid 44865162)
19. Mokrousov I, et al. 2008. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob. Agents Chemother. 52:2937-2939.
20. Pantel A, et al. 2011. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:4765-4771.
21. Pitaksajjakul P, et al. 2005. Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J. Trop. Med. Public Health 36(Suppl. 4):228-237.
22. Piton J, et al. 2010. Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One 5:e12245.
23. Poissy J, et al. 2010. Should moxifloxacin be used for the treatment of XDR-TB? An answer from the murine model. Antimicrob. Agents Chemother. 54:4765-4771.
24. Sun Z, et al. 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents 31:115-121.
25. Takiff HE, et al. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780. (Pubitemid 24114017)
26. van Doorn HR, et al. 2008. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int. J. Tuberc. Lung Dis. 12:736-742.
27. Veziris N, et al. 2007. Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur. J. Clin. Microbiol. Infect. Dis. 26:423-425. (Pubitemid 46872994)
28. Von Groll A, et al. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500.
29. Wang JY, et al. 2007. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J. Antimicrob. Chemother. 59:860-865.
30. World Health Organization. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization, Geneva, Switzerland.
31. World Health Organization. 2011. Progress report 2011. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. World Health Organization, Geneva, Switzerland.
32. Yin X, Yu Z. 2010. Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. J. Infect. 61:150-154.
33. Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35:1647-1650.